Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manabu Morimoto

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
Cancers|January 30, 2020
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Haruki Uojima, Kazushi Numata, et al.
Internal Medicine (Tokyo, Japan)|June 2, 2017
The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori EradicationSoichiro Sue, Hirofumi Kuwashima, Yuri Iwata, et al.
Clinical and Experimental Gastroenterology|October 16, 2020
Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter AnalysisKatsuaki Ogushi, Makoto Chuma, Haruki Uojima, et al.
The Lancet. Oncology|January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialAndrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
Current Oncology (Toronto, Ont.)|May 27, 2022
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib TreatmentMakoto Chuma, Hideki Yokoo, Atsushi Hiraoka, et al.
Hepatology (Baltimore, Md.)|May 19, 2025
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trialGeorge Lau, Bruno Sangro, Ann-Lii Cheng, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2020
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysisMakoto Chuma, Haruki Uojima, Atsushi Hiraoka, et al.
Hepatology International|August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.
The American Journal of Gastroenterology|December 12, 2025
Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B studyJie Li, Joanne Kimiko Liu, Angela Chau, et al.
Nature Communications|June 26, 2020
Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancerYingsong Lin, Masahiro Nakatochi, Yasuyuki Hosono, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Cancers|January 30, 2020
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Haruki Uojima, Kazushi Numata, et al.
Internal Medicine (Tokyo, Japan)|June 2, 2017
The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori EradicationSoichiro Sue, Hirofumi Kuwashima, Yuri Iwata, et al.
Clinical and Experimental Gastroenterology|October 16, 2020
Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter AnalysisKatsuaki Ogushi, Makoto Chuma, Haruki Uojima, et al.
The Lancet. Oncology|January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialAndrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
Current Oncology (Toronto, Ont.)|May 27, 2022
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib TreatmentMakoto Chuma, Hideki Yokoo, Atsushi Hiraoka, et al.
Hepatology (Baltimore, Md.)|May 19, 2025
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trialGeorge Lau, Bruno Sangro, Ann-Lii Cheng, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2020
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysisMakoto Chuma, Haruki Uojima, Atsushi Hiraoka, et al.
Hepatology International|August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.
The American Journal of Gastroenterology|December 12, 2025
Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B studyJie Li, Joanne Kimiko Liu, Angela Chau, et al.
Nature Communications|June 26, 2020
Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancerYingsong Lin, Masahiro Nakatochi, Yasuyuki Hosono, et al.
Pageof 16